Zydus receives EIR from USFDA for its injectables manufacturing facility at Jarod

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), an innovation driven global lifesciences company announced that it has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Jarod injectables manufacturing facility near Vadodara, India. Zydus said that the USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI) and has concluded that the inspection is considered as "closed" under 21 CFR 20.64(d)(3). The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs. The USFDA had inspected the facility from 24th February to 10th March, 2022.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 373.65 as compared to the previous close of Rs. 372.85. The total number of shares traded during the day was 79403 in over 2384 trades.

The stock hit an intraday high of Rs. 376.50 and intraday low of 371.25. The net turnover during the day was Rs. 29699421.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA EIR Jarod InjectablesManufacturingFacility Vadodara